What is TTRX's additional paid-in capital?

TTRX (TTRX) reported additional paid-in capital of $29.48M in Q1 2026.

What does additional paid-in capital mean?

Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.

TTRX TTRX Additional Paid-In Capital

Additional Paid-In Capital at other companies

Regeneron PharmaceuticalsREGN

$14.4B+9.2%

Bausch Health CompaniesBHC

$295M+34.1%

Journey Medical CorporationDERM

$131.52M+16.8%

PTH

Pelthos Therapeutics Inc.PTHS

$106.95M+456%

Celldex TherapeuticsCLDX

$2.35B+1.6%

Arcutis Biotherapeutics, Inc.ARQT

$1.34B+3.9%

Other financials

Income statement

See full

Operating income-$1.2M-224%

Net income-$971.0K-196%

EPS (diluted)-$0.03-200%

Balance sheet

See full

Cash & equivalents$11.2M+613%

Total debt$6.0M—

Total equity$6.1M+647%

Total assets$18.6M—

Cash flow

See full

Operating cash flow-$1.6M-448%

Valuation

See full

Market cap$217.45M-17.7%

Enterprise value$212.24M—

Returns & leverage

See full

Return on equity-118.8%—

Debt / equity1×—

Current ratio2.2×—

Where this comes from

Reported directly by TTRX in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: TTRX’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about TTRX's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is TTRX's additional paid-in capital?: TTRX (TTRX) reported additional paid-in capital of $29.48M in Q1 2026.
What does additional paid-in capital mean?: Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.